KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortizatization of IntangiblesBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pacira BioSciences (PCRX) Cash from Financing Activities: 2009-2024

Historic Cash from Financing Activities for Pacira BioSciences (PCRX) over the last 16 years, with Dec 2024 value amounting to $17.4 million.

  • Pacira BioSciences' Cash from Financing Activities fell 8950.12% to -$257.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$319.9 million, marking a year-over-year decrease of 1924.11%. This contributed to the annual value of $17.4 million for FY2024, which is 109.49% up from last year.
  • Pacira BioSciences' Cash from Financing Activities amounted to $17.4 million in FY2024, which was up 109.49% from -$183.0 million recorded in FY2023.
  • Over the past 5 years, Pacira BioSciences' Cash from Financing Activities peaked at $380.7 million during FY2021, and registered a low of -$401.5 million during FY2022.
  • Moreover, its 3-year median value for Cash from Financing Activities was -$183.0 million (2023), whereas its average is -$189.1 million.
  • Its Cash from Financing Activities has fluctuated over the past 5 years, first soared by 5,957.33% in 2020, then slumped by 205.47% in 2022.
  • Pacira BioSciences' Cash from Financing Activities (Yearly) stood at $222.3 million in 2020, then skyrocketed by 71.25% to $380.7 million in 2021, then crashed by 205.47% to -$401.5 million in 2022, then skyrocketed by 54.42% to -$183.0 million in 2023, then surged by 109.49% to $17.4 million in 2024.